TrialClinical drug investigation2021

First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.

Khalid Abd-Elaziz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.